(Q60563341)

English

Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants

clinical trial

In more languages

edit

Statements

instance of

multicenter clinical trial

0 references

title

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years (English)

0 references

sponsor

Takeda Pharmaceutical Company

0 references

country

United States of America

0 references

located in the administrative territorial entity

0 references

1 reference

13 November 2017

0 references

end time

19 November 2020

0 references

number of participants

240

0 references

research intervention

placebo

0 references

clinical trial phase

phase I clinical trial

0 references

research site

Clinical Research of South Florida

0 references

medical condition treated

0 references

0 references

0 references

Identifiers

ClinicalTrials.gov ID

NCT03343626

0 references

(Q60563341)

Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)